Hamilton Reef
09-18-2005, 03:08 PM
Deer contraceptive fails in Jersey test
http://www.nj.com/news/ledger/jersey/index.ssf?/base/news-1/112701990998290.xml&coll=1
Sunday, September 18, 2005 BY BRIAN T. MURRAY Star-Ledger Staff
Brian Murray may be reached at (973) 392-4153 or bmurray@starledger.com.
The two dozen white-spotted fawns prancing around Princeton Township a few months ago were a signal something was wrong.
Their mothers were among 52 female deer injected last year with the birth control vaccine SpayVac, a drug expected to one day help manage wildlife populations.
But the fawns in Mercer County and another group in Ohio whose mothers also had been inoculated have put SpayVac on the shelf for good.
Along with it went the hopes for what wildlife biologists have sought for more than 20 years: an environmentally sound deer contraceptive that could be applied with one easy shot and last for years.
"It looked very promising, but now it's going to sit on a shelf and that's unfortunate," said Anthony DiNicola, a biologist and president of White Buffalo Inc., which was conducting the New Jersey experiment in conjunction with the state Division of Fish & Wildlife.
With white-tailed deer causing traffic collisions and devouring the countryside, biologists and wildlife education groups had hoped to supplement hunting efforts with a vaccine, particularly in suburban enclaves where hunters cannot tread. Today, there are an estimated 200,000 deer in New Jersey.
"It's (still) worth exploring because while hunting is the most effective tool, deer are now in urban corners where lethal control is not possible even for those outfits ... who use sharpshooters," said Larry Herrighty, head of the state's Bureau of Wildlife Management.
SpayVac seemed to be the answer and the state allowed a test program this year after an early version of the vaccine used at Penn State University three years ago showed promise. Despite regular mating, none of the test deer in that experiment has become pregnant.
The drug's failure in New Jersey and Ohio, according to company officials, resulted from a change in the manufacturing process needed to meet the federal Food and Drug Administration's sterilization standards.
"The vaccine was heated to higher temperatures than normal," explained Mark Fraker, president of SpayVac for Wildlife Inc. and TerraMar Environmental Research Ltd. of British Columbia, Canada.
The manufacturing change was a necessary and expected next step for SpayVac developers, who were venturing into the costly and lengthy process of seeking FDA approval so SpayVac could be pushed beyond the laboratory and into the public market.
That is not going to happen now.
ImmunoVaccine Technologies Inc. of Nova Scotia, which owns the patent and rights to manufacture SpayVac, has stopped funding the project.
"The main issue is that to take it further through the FDA process can cost $2 million to $3 million, even maybe $4 million," said Robert Brown, chief science officer at IVT. "We're a private company, and we were supporting the SpayVac program although it was at a loss. We don't see a future in getting it to the market. ... It's not commercially viable."
The failure left DiNicola and White Buffalo scrambling to round up the deer and apply another test vaccine that is known as GnRH. DiNicola was able to revaccinate 39 of the deer last month.
"He was already allowed to use GnRH on some of his deer in Princeton, so I authorized a change. The state has to be flexible with its research projects because of potential problems like this," Herrighty said.
It's too early to know if GnRH will be the silver bullet in deer birth control. But SpayVac's troubles have served as another reminder how difficult it is to develop a one-shot, long-lasting vaccine.
"The high costs of using birth control on wildlife are in the logistics of capturing and applying the vaccine," Herrighty said. "Those costs would be reduce drastically by a one-shot, long-lasting fertility program."
DiNicola, who would not put a price tag on the experiment, said he is looking ahead.
Although GnRH may last only two to four years, researchers hope to extend its effectiveness, he said. Its other advantage is that it prevents female deer from going into estrus, or heat, he added. That means the does are less likely to be hit by cars because male deer will not chase them in mating season.
"Where SpayVac was the leading vaccine, there is now GnRH. The tortoise is now in the lead," DiNicola said.
http://www.nj.com/news/ledger/jersey/index.ssf?/base/news-1/112701990998290.xml&coll=1
Sunday, September 18, 2005 BY BRIAN T. MURRAY Star-Ledger Staff
Brian Murray may be reached at (973) 392-4153 or bmurray@starledger.com.
The two dozen white-spotted fawns prancing around Princeton Township a few months ago were a signal something was wrong.
Their mothers were among 52 female deer injected last year with the birth control vaccine SpayVac, a drug expected to one day help manage wildlife populations.
But the fawns in Mercer County and another group in Ohio whose mothers also had been inoculated have put SpayVac on the shelf for good.
Along with it went the hopes for what wildlife biologists have sought for more than 20 years: an environmentally sound deer contraceptive that could be applied with one easy shot and last for years.
"It looked very promising, but now it's going to sit on a shelf and that's unfortunate," said Anthony DiNicola, a biologist and president of White Buffalo Inc., which was conducting the New Jersey experiment in conjunction with the state Division of Fish & Wildlife.
With white-tailed deer causing traffic collisions and devouring the countryside, biologists and wildlife education groups had hoped to supplement hunting efforts with a vaccine, particularly in suburban enclaves where hunters cannot tread. Today, there are an estimated 200,000 deer in New Jersey.
"It's (still) worth exploring because while hunting is the most effective tool, deer are now in urban corners where lethal control is not possible even for those outfits ... who use sharpshooters," said Larry Herrighty, head of the state's Bureau of Wildlife Management.
SpayVac seemed to be the answer and the state allowed a test program this year after an early version of the vaccine used at Penn State University three years ago showed promise. Despite regular mating, none of the test deer in that experiment has become pregnant.
The drug's failure in New Jersey and Ohio, according to company officials, resulted from a change in the manufacturing process needed to meet the federal Food and Drug Administration's sterilization standards.
"The vaccine was heated to higher temperatures than normal," explained Mark Fraker, president of SpayVac for Wildlife Inc. and TerraMar Environmental Research Ltd. of British Columbia, Canada.
The manufacturing change was a necessary and expected next step for SpayVac developers, who were venturing into the costly and lengthy process of seeking FDA approval so SpayVac could be pushed beyond the laboratory and into the public market.
That is not going to happen now.
ImmunoVaccine Technologies Inc. of Nova Scotia, which owns the patent and rights to manufacture SpayVac, has stopped funding the project.
"The main issue is that to take it further through the FDA process can cost $2 million to $3 million, even maybe $4 million," said Robert Brown, chief science officer at IVT. "We're a private company, and we were supporting the SpayVac program although it was at a loss. We don't see a future in getting it to the market. ... It's not commercially viable."
The failure left DiNicola and White Buffalo scrambling to round up the deer and apply another test vaccine that is known as GnRH. DiNicola was able to revaccinate 39 of the deer last month.
"He was already allowed to use GnRH on some of his deer in Princeton, so I authorized a change. The state has to be flexible with its research projects because of potential problems like this," Herrighty said.
It's too early to know if GnRH will be the silver bullet in deer birth control. But SpayVac's troubles have served as another reminder how difficult it is to develop a one-shot, long-lasting vaccine.
"The high costs of using birth control on wildlife are in the logistics of capturing and applying the vaccine," Herrighty said. "Those costs would be reduce drastically by a one-shot, long-lasting fertility program."
DiNicola, who would not put a price tag on the experiment, said he is looking ahead.
Although GnRH may last only two to four years, researchers hope to extend its effectiveness, he said. Its other advantage is that it prevents female deer from going into estrus, or heat, he added. That means the does are less likely to be hit by cars because male deer will not chase them in mating season.
"Where SpayVac was the leading vaccine, there is now GnRH. The tortoise is now in the lead," DiNicola said.